PharmaCom BioVet, Inc. Comments on Speculation of Corporate Restructuring
March 16 2009 - 3:34PM
Marketwired
PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to comment on
shareholder and investor speculation of any potential amendments to
the existing capital structure including the possibility of any
consolidation of the existing issued and outstanding common stock.
At the present time, PharmaCom BioVet, Inc. has no intention to
amend the current capital structure of the company in any format.
Any material changes to the corporate structure will require
shareholder approval by way of a vote at either the annual general
meeting or by way of a vote at an extraordinary meeting of
shareholders.
Any potential amendment to the capital structure, as determined
and therefore proposed by management to its shareholders, will be
in the best interest of those who have invested in PharmaCom
BioVet, Inc. and to the company as a whole.
About Us:
PharmaCom BioVet, Inc. is quickly positioning itself to becoming
the leader in specialized veterinary oncology (cancer treatment
facilities for animals). PHMB management is planning the rollout of
specialized Veterinary Oncology Treatment Centers that will be
strategically located throughout the United States. PHMB has
licensed a series of proprietary devices and compounds that will
enable animals suffering from cancer a potentially greater life
expectancy and decreased suffering.
On behalf of the Board of Directors,
Mr. Gary Berthold
DISCLOSURE:
"Safe Harbor" statement under the Private Securities Litigation
Reform Act of 1995: This press release contains forward-looking
statements that are subject to risk and uncertainties, including,
but not limited to, the impact of competitive products, product
demand, market acceptance risks, fluctuations in operating results,
political risk and other risks detailed from time to time in
PharmaCom BioVet, Inc.'s filings with the Securities and Exchange
Commission. These risks could cause PharmaCom BioVet, Inc.'s actual
results to differ materially from those expressed in any
forward-looking statements made by, or on behalf of, PharmaCom
BioVet, Inc.
Contact: Mr. Gary Berthold Tel: (919) 701-4574 Url:
www.PharmaComBioVet.com
PharmaCom BioVet (CE) (USOTC:PHMB)
Historical Stock Chart
From Oct 2024 to Nov 2024
PharmaCom BioVet (CE) (USOTC:PHMB)
Historical Stock Chart
From Nov 2023 to Nov 2024